ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
Aish SinhaHaseeb RahmanAbdel DouiriOzan M DemirKalpa De SilvaBrian ClappIan WebbAnkur GulatiPedro PinhoUtkarsh DuttaHoward EllisAjay M ShahAmedeo ChiribiriMichael MarberAndrew James WebbDivaka PereraPublished in: Circulation (2023)
Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group.
Keyphrases
- phase iii
- placebo controlled
- coronary artery disease
- phase ii
- coronary artery
- double blind
- study protocol
- open label
- clinical trial
- case report
- percutaneous coronary intervention
- ischemia reperfusion injury
- randomized controlled trial
- heart failure
- cerebral ischemia
- acute coronary syndrome
- brain injury
- left ventricular
- aortic stenosis
- blood flow
- cell therapy
- bone marrow
- atrial fibrillation
- ejection fraction